DefenAge

Skincare's defensin story actually begins in the messy biology of wounds. Defensins are antimicrobial peptides the body deploys during healing, and the Carlsbad researchers studying them were chasing chronic problems like diabetic ulcers, not crow's feet. The cosmetic angle emerged from a specific finding: certain defensins appear to rouse dormant LGR6-positive stem cells, sometimes nicknamed the skin's master cells for their ability to differentiate into every epidermal type, prompting them to migrate up and lay down fresh epidermis. That mechanism, rather than exfoliation or inflammation, is what the brand stakes its retinol-alternative claim on. Commercially it crept rather than burst onto the scene. After a quiet 2015 soft launch, the line spread through aesthetic physicians' offices and medi-spas, reportedly tripling sales year over year and clearing several million dollars within a couple of years, an unusually slow, clinical-channel rollout for an anti-aging brand. The company also kept feeding the research pipeline: a three-step-system trial appeared in the Journal of Drugs in Dermatology, and a later study on a defensin body cream ran in the Journal of Cosmetic Dermatology, reporting measurable gains in skin thickness, hydration and elasticity. The flagship eight-step BioSerum carries the heaviest peptide load, anchoring a small line built around the same proprietary molecules. The candid caveat is structural rather than cynical: because defensins are an exclusive, single-source technology, most of the validating science is generated or funded by the people who sell it, and the mechanism, however intriguing, simply hasn't accumulated the independent, decades-deep replication that proven actives enjoy. The premise is legitimately novel; the evidence base is narrow, and the luxury pricing asks buyers to fund a still-young scientific bet.

Sources:[1][2][3]